title: Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy.
abstract: Advanced congestive heart failure (CHF) and chronic kidney disease (CKD) are characterized by increased angiotensin II (Ang II) levels and are often accompanied by significant skeletal muscle wasting that negatively impacts mortality and morbidity. Both CHF and CKD patients have respiratory muscle dysfunction, however the potential effects of Ang II on respiratory muscles are unknown. We investigated the effects of Ang II on diaphragm muscle in FVB mice. Ang II induced significant diaphragm muscle wasting (18.7±1.6% decrease in weight at one week) and reduction in fiber cross-sectional area. Expression of the E3 ubiquitin ligases atrogin-1 and muscle ring finger-1 (MuRF-1) and of the pro-apoptotic factor BAX was increased after 24 h of Ang II infusion (4.4±0.3 fold, 3.1±0.5 fold and 1.6±0.2 fold, respectively, compared to sham infused control) suggesting increased muscle protein degradation and apoptosis. In Ang II infused animals, there was significant regeneration of injured diaphragm muscles at 7 days as indicated by an increase in the number of myofibers with centralized nuclei and high expression of embryonic myosin heavy chain (E-MyHC, 11.2±3.3 fold increase) and of the satellite cell marker M-cadherin (59.2±22.2% increase). Furthermore, there was an increase in expression of insulin-like growth factor-1 (IGF-1, 1.8±0.3 fold increase) in Ang II infused diaphragm, suggesting the involvement of IGF-1 in diaphragm muscle regeneration. Bone-marrow transplantation experiments indicated that although there was recruitment of bone-marrow derived cells to the injured diaphragm in Ang II infused mice (267.0±74.6% increase), those cells did not express markers of muscle stem cells or regenerating myofibers. In conclusion, Ang II causes marked diaphragm muscle wasting, which may be important for the pathophysiology of respiratory muscle dysfunction and cachexia in conditions such as CHF and CKD.
authors.affiliation: Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
authors.forename: Bashir M
authors.initials: BM
authors.lastname: Rezk
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Laura
authors.initials: L
authors.lastname: Semprun-Prieto
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Higashi
authors.forename: Sergiy
authors.initials: S
authors.lastname: Sukhanov
authors.forename: Patrice
authors.initials: P
authors.lastname: Delafontaine
mesh_terms: D000804:Angiotensin II / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D003964:Diaphragm / Q000187:drug effects* / Q000378:metabolism*; D005434:Flow Cytometry; D015151:Immunoblotting; D008297:Male; D051379:Mice; D009124:Muscle Proteins / Q000235:genetics / Q000378:metabolism; D018482:Muscle, Skeletal / Q000378:metabolism / Q000473:pathology; D009133:Muscular Atrophy / Q000139:chemically induced* / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D012038:Regeneration / Q000502:physiology; D000070584:Tripartite Motif Proteins; D044767:Ubiquitin-Protein Ligases / Q000235:genetics / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism
chemical_list: C494827:Bax protein, mouse; D009124:Muscle Proteins; D000070584:Tripartite Motif Proteins; D051028:bcl-2-Associated X Protein; D000804:Angiotensin II; C499084:Trim63 protein, mouse; D044767:Ubiquitin-Protein Ligases